- $2.45bn
- $2.71bn
- $510.67m
- 36
- 50
- 19
- 27
Annual balance sheet for Core Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 8.67 | 118 | 15.9 | 50.4 | 836 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.11 | 1.68 | 0.257 | 1 | 1.02 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 70.9 | 757 | 85.1 | 97 | 904 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 85.2 | 597 | 712 | 593 | 671 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 226 | 2,439 | 808 | 712 | 1,599 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 69.6 | 320 | 187 | 488 | 135 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 91.9 | 1,053 | 1,217 | 1,309 | 2,419 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 134 | 1,386 | -409 | -597 | -820 |
| Total Liabilities & Shareholders' Equity | 226 | 2,439 | 808 | 712 | 1,599 |
| Total Common Shares Outstanding |